GlassScriptPhysician profile
Viviane Andersen
NPI 1679904486
$6,037.38
in general payments reported to CMS, 2019-2025
24 companies · $817 in 2025
The $817 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $810 · 2022: $1,464 · 2023: $1,660 · 2024: $1,287 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,763.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,542.20 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $642.09 | 2021-2024 | Xifaxan, Trulance |
| Celgene Corporation | $598.99 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $462.76 | 2021-2024 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $411.19 | 2021-2024 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $322.02 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $278.28 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $261.14 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $173.76 | 2021-2024 | Ocaliva |
| Ardelyx, INC. | $160.98 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $149.02 | 2021-2023 | Rebyota, Clenpiq |
| Gilead Sciences, INC. | $126.06 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $125.52 | 2022-2024 | Linzess |
| Qol Medical, LLC | $124.89 | 2021-2023 | Sucraid |
| Merck Sharp & Dohme LLC | $112.97 | 2021-2024 | Dificid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $107.03 | 2022-2024 | |
| Genzyme Corporation | $101.80 | 2023-2024 | |
| Braintree Laboratories, INC. | $91.41 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $50.09 | 2024 | |
| Mallinckrodt Hospital Products INC. | $43.02 | 2024-2025 | Terlivaz |
| Lilly USA, LLC | $42.90 | 2024 | Omvoh |
| Fresenius Kabi USA, LLC | $41.59 | 2023 | Idacio |
| Amgen INC. | $40.34 | 2023 | Avsola, Amjevita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.33 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viviane Andersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.